Radius reports additional Phase I data for breast cancer candidate

Radius Health Inc. (NASDAQ:RDUS) reported additional data from the Phase I RAD1901-005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced

Read the full 259 word article

User Sign In